Home › Myelodysplastische syndromen › Texas › Houston
Myelodysplastische syndromen klinische studies in Houston, TX
43 studies voor Myelodysplastische syndromen zoeken deelnemers op locaties in en rond Houston (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruterenFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekruterenFase 1
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
RekruterenFase 1/2
- MD Anderson Cancer Center, Houston
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
RekruterenFase 1/2
- M D Anderson Cancer Center, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RekruterenFase 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RekruterenFase 1
- M D Anderson Cancer Center, Houston
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RekruterenFase 3
- The University of Texas-MD Anderson Cancer Center - Leukemia Center, Houston
- LUMI Research, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
RekruterenFase 1/2
- M D Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RekruterenFase 2
- M D Anderson Cancer Center, Houston
A Study of BGB-11417 in Participants With Myeloid Malignancies
RekruterenFase 1/2
- Md Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RekruterenFase 2Gezonde vrijwilligers welkom
- MD Anderson Cancer Center, Houston
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
RekruterenFase 1
- The University of Texas MD Anderson Cancer Center, Houston
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RekruterenFase 1/2
- M D Anderson Cancer Center, Houston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RekruterenFase 3
- MD Anderson Cancer Centre, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RekruterenFase 2
- M D Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruterenFase 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RekruterenFase 3
- U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
RekruterenFase 2
- Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
RekruterenFase 2/3Gezonde vrijwilligers welkom
- M D Anderson Cancer Center, Houston
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RekruterenFase 1/2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RekruterenFase 1/2
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
RekruterenFase 2
- M D Anderson Cancer Center, Houston
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
RekruterenFase 1/2
- Research Site, Houston
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RekruterenFase 2
- University of Texas MD Anderson Cancer Center, Houston
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RekruterenFase 2
- M D Anderson Cancer Center, Houston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
RekruterenFase 1
- MD Anderson Cancer Center, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
RekruterenFase 1
- MD Anderson Cancer Center, Houston
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
RekruterenFase 2
- M D Anderson Cancer Center, Houston
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RekruterenFase 2
- GSK Investigational Site, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
RekruterenFase 1
- MD Anderson, Houston
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
RekruterenFase 1
- MD Anderson, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
RekruterenFase 2
- M D Anderson Cancer Center, Houston
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RekruterenFase 2
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruterenFase 2/3
- MD Anderson Cancer Center, Houston
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
RekruterenFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
RekruterenFase 1
- MD Anderson Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruterenFase 1/2
- MDACC, Houston
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
RekruterenFase 1
- MD Anderson, Houston
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
RekruterenFase 1Gezonde vrijwilligers welkom
- M.D. Anderson Cancer Center, Department of Leukemia, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Houston
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekruterenFase 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Study of REM-422 in Patients With AML or Higher Risk MDS
RekruterenFase 1
- MD Anderson Cancer Center, Houston
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RekruterenFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Myelodysplastische syndromen studies in andere steden
- Baldwin Park, CA26 studies
- New York City, NY21 studies
- Seattle, WA21 studies
- Washington, DC20 studies
- Tampa, FL19 studies
- Boston, MA19 studies
- Miami, FL17 studies
- Durham, NC14 studies
- Columbus, OH14 studies
- St. Louis, MO13 studies
- Atlanta, GA13 studies
- Chicago, IL13 studies
Andere studies in Houston
- Niet-kleincellige longkanker145 studies
- Borstkanker126 studies
- Kanker (alle vormen)121 studies
- Metastatische kanker104 studies
- Colorectale kanker102 studies
- Eierstokkanker89 studies
- Acute myeloïde leukemie85 studies
- Longkanker78 studies
- Prostaatkanker76 studies
- Endometriumkanker68 studies
- Aldermeesklierkanker61 studies
- Melanoom59 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.